Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense gemcitabine + carboplatin with pegfilgrastim as neoadjuvant therapy for operable stage IIIA NSCLC
2005-001005-26Phase 2Active
- Sponsor
- Fundación GECP
- Start
- May 2006
- Modality
- Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, carboplatin and pegfilgrastim in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Primary endpoint: Feasibility of neoadjuvant dose-dense gemcitabine + carboplatin with pegfilgrastim at planned dose and schedule. Started May 2006; status: active.
02
Drugs
gemcitabinecarboplatinpegfilgrastim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-001005-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001005-26.